Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

CANCER:

Urothelial Cancer

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related cancers:

‹

Bladder Cancer (181)

Bladder Cancer (181)

›

PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	avelumab Sensitive: A1 - Approval avelumab Sensitive : A1	avelumab Sensitive: A1 - Approval avelumab Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1	sacituzumab govitecan-hziy Sensitive: A1 - Approval sacituzumab govitecan-hziy Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	mitomycin urothelial gel Sensitive: A1 - Approval mitomycin urothelial gel Sensitive : A1	mitomycin urothelial gel Sensitive: A1 - Approval mitomycin urothelial gel Sensitive : A1
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	enfortumab vedotin-ejfv Sensitive: A1 - Approval enfortumab vedotin-ejfv Sensitive : A1	enfortumab vedotin-ejfv Sensitive: A1 - Approval enfortumab vedotin-ejfv Sensitive : A1
FGFR2 mutation	Urothelial Cancer	FGFR2 mutation	Urothelial Cancer	erdafitinib Sensitive: A1 - Approval erdafitinib Sensitive : A1	erdafitinib Sensitive: A1 - Approval erdafitinib Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
FGFR3 mutation	Urothelial Cancer	FGFR3 mutation	Urothelial Cancer	erdafitinib Sensitive: A1 - Approval erdafitinib Sensitive : A1	erdafitinib Sensitive: A1 - Approval erdafitinib Sensitive : A1